Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study

AIM: At present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed. In this study, we aimed to examine the possible effects of once-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanada, Junpei, Kimura, Tomohiko, Shimoda, Masashi, Tomita, Akiko, Fushimi, Yoshiro, Kinoshita, Tomoe, Obata, Atsushi, Okauchi, Seizo, Hirukawa, Hidenori, Kohara, Kenji, Tatsumi, Fuminori, Nakanishi, Shuhei, Mune, Tomoatsu, Kaku, Kohei, Kaneto, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415741/
https://www.ncbi.nlm.nih.gov/pubmed/34484124
http://dx.doi.org/10.3389/fendo.2021.714447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415741/
https://www.ncbi.nlm.nih.gov/pubmed/34484124
http://dx.doi.org/10.3389/fendo.2021.714447

Ejemplares similares